Our Indication Assessment service for life sciences organizations provides a rigorous framework for evaluating new therapeutic indications. We combine epidemiological modeling, treatment landscape analysis, and competitive pipeline assessment to identify high-value indications for your assets. Our approach integrates scientific evidence from 250M+ research papers with commercial analysis to bridge the gap between scientific potential and commercial opportunity.
How our indication assessment service delivers value to your organization.
Leverage 250M+ research papers to build a comprehensive evidence base for each indication under consideration.
Quantitative unmet need scoring that combines treatment gaps, outcome limitations, and patient burden.
Assess the competitive pipeline for each indication to identify windows of opportunity and differentiation.
Evaluate each indication against your scientific capabilities, platform technology, and corporate strategy.
Comprehensive deliverables that provide actionable intelligence for your team.
A structured methodology that delivers results in four phases.
Systematic review of 250M+ research papers to build the evidence base for each indication.
Develop epidemiological models with patient segmentation and disease progression analysis.
Assess the competitive landscape including approved therapies and pipeline products.
Deliver evidence-based recommendation with strategic rationale and development roadmap.
We use AI-powered search across 250M+ research papers to identify relevant evidence on disease mechanisms, treatment outcomes, and emerging therapeutic approaches for each indication.
Yes, we specialize in evaluating indications for platform technologies including gene therapy, cell therapy, and RNA-based therapeutics.
A typical indication assessment takes 4-6 weeks, depending on the complexity of the therapeutic area and the number of indications under evaluation.
Comprehensive therapy area deep-dives covering market dynamics, competitive landscape, pipeline products, and emerging trends.
Learn moreIdentify and analyze Key Opinion Leaders across 90M+ global experts with proprietary influence scoring and network mapping.
Learn moreData-driven R&D portfolio assessment with risk-adjusted valuation, resource allocation, and strategic fit analysis.
Learn moreConnect with our team to discuss how our indication assessment service can support your goals.
Schedule a Consultation